Loading
A London-built breast screening AI trialled across NHS sites as a second reader, now folded into RadNet's DeepHealth after a 2024 acquisition.
Kheiron Medical Technologies (founded in London in 2016) received the CE mark for Mia in 2019 and won an NHS AI in Health and Care Award in 2020, which funded prospective evaluation of Mia as an independent second reader in NHS breast screening units, including a service evaluation in NHS Grampian. Retrospective multi-site studies in the UK and Hungary reported non-inferior performance to human readers. In 2024 Kheiron became part of DeepHealth, RadNet's AI subsidiary, and Mia's technology was integrated into DeepHealth's SmartMammo. The UK's national evaluation of AI in breast screening (the EDITH trial, announced 2025) will test several products at scale.
Deep-learning reader trained on multi-vendor mammograms, designed to act as an independent second reader in double-reading programmes such as the NHS Breast Screening Programme.
1.Mia (Mammography Intelligent Assessment) slips into a pocket on its target.
| Region | Year | Indication |
|---|---|---|
| EU | 2019 | CE mark, mammography decision support |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Mia" OR ABSTRACT:"Mia" OR TITLE:"Mammography Intelligent Assessment" OR ABSTRACT:"Mammography Intelligent Assessment") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mia (Mammography Intelligent Assessment), not a curated reading list.
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Mammography & tomosynthesis, AI in radiology, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares AI in radiology and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag test.